Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) | MicrobiomeTrials← Back to trialsNCT05177211
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2022-03-01Est. Completion: 2025-04-10
Enrollment target: 25 participants Locations- Moffitt Cancer Center, Tampa, Florida, United States
- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
- Cleveland Clinic, Cleveland, Ohio, United States
Other microbiome trials you might be interested in
JAK2 Mutation
The goal of this clinical trial is to learn if the drug ropeginterferon alfa-2b can be used safely to treat patients wit…
Boston, United StatesEst. completion Aug 2030
Disease/Condition Name Cancer-related Cognitive DysfunctionChronic Lymphocytic Leukemia (CLL)Chronic Myeloid Leukemia, BCR-ABL1 Positive
This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for le…
Rochester, United StatesEst. completion Feb 28, 2029
Myelodysplastic SyndromesMDSMyelodysplastic Syndrome, UnclassifiableHematologic DiseasesBone Marrow DiseaseMyeloproliferative Neoplasm
This study will be conducted as a phase 1/2 study of safety and preliminary efficacy of pacritinib in combination with a…
Multiple LocationsEst. completion Jan 2027